http://www.ijdrt.com 231
Int. J. Drug Res. Tech. 2012, Vol. 2 (3), 231-238 ISSN 2277 - 1506
International Journal of Drug Research and Technology
Available online at http://www.ijdrt.com/
Review Article
IMPURITY PROFILING OF ACTIVE PHARMACEUTICAL INGREDIENTS
AND FINISHED DRUG PRODUCTS
Renu Solanki
Lachoo Memorial College of Science and Technology, Pharmacy Wing,
Jodhpur, Rajasthan, India
ABSTRACT
Pharmaceuticals impurities are the unwanted chemicals that remain or are generated during the
formulation of medicines. Impurity profiling helps in detection, identification and quantification of
various types of impurities as well as residual solvents in bulk drugs and in pharmaceutical formulations.
It is a best way to characterize quality and stability of bulk drugs and pharmaceutical formulations. Due to
rapid development of the analytical methodology it is imperative to review problems related to impurities
present in the drug substances and drug products with their solutions. Various regulatory authorities like
ICH, USFDA, Canadian Drug and Health Agencies are emphasizing on the purity requirements and on
identification of impurities in active pharmaceutical ingredients as presence of impurities even in small
amounts may influence the efficacy and safety of the pharmaceutical products. Thus enlightening the
need of impurity profiling of drug substances in pharmaceutical research this review focuses on various
analytical methods for identification as well as quantification of impurities present in the pharmaceuticals.
Keywords: Bulk drugs, Impurities, Formulation, Analytical method development.
INTRODUCTION
IMPURITY
Pharmaceuticals impurities are the unwanted
chemicals that remain with the active
pharmaceutical ingredients (APIs) or are
developed during formulation or upon aging of
both API and formulated APIs to medicines. The
presence of these unwanted chemicals even in
small amounts may influence the efficacy and
safety of the pharmaceutical products
1
.
IMPURITY PROFILING
It gives an account of impurities present in the
bulk and finished drug. It helps in identifying and
quantifying the impurities present in drug
substance (API) or pharmaceutical formulation. It
gives maximum possible types of impurities
present in drug substance (API) and in
pharmaceutical formulations
1
.
CLASSIFICATION OF IMPURITIES
Impurities are classified on the basis of
pharmacopeia and guidelines:
As per United State Pharmacopoeia
The United States Pharmacopoeia (USP)
classifies impurities in two sections-ordinary
impurities and organic volatile impurities.
Ordinary Impurities
Ordinary impurities are found in bulk
pharmaceutical chemicals that are innocuous by
virtue of having no significance on biological
activity of the drug substance. These impurities
may arise out of the synthesis, preparation or
degradation of chemical.
Organic Volatile Impurities
Organic volatile chemicals are produced in the
manufacture of drug substances or excipients or in
Renu Solanki et al. / International Journal of Drug Research and Technology 2012, Vol. 2 (3), 231-238
http://www.ijdrt.com 232
the preparation of drug products, they are volatile
in nature and by themselves get removed out at
time of storage or processing
2
.
As per ICH Guidelines
The ICH guideline classifies impurities in three
sections- organic, inorganic and process based
impurities.
Organic Impurities
Such type of impurities arises during
manufacturing process and/or during storage of
the drug substance. These include starting or
intermediate impurities, by-products impurities,
degraded products impurities and enantiomeric
impurities.
2,3
Starting Materials or Intermediates Impurities
These are common type of impurities which are
found in almost every API unless a proper care is
taken in every step involved throughout the multi-
step synthesis of drug product. Although the end
products are always washed with solvents but
there are chances of having the residual of
unreacted starting materials unless the
manufacturers are very careful about the
impurities. Eg. in paracetamol bulk, there is a
limit test for p-aminophenol, which could be a
starting material for some manufacturer or be an
intermediate for another.
3
By-Products Impurities
In synthetic organic chemistry, getting a single
end product with 100% yield is very rare as there
is always a chance of having some by-products
along with desired end product. Eg. in case of
paracetamol bulk, diacetylated paracetamol may
form as a by-product.
Degraded Products Impurities
Impurities can also be formed by degradation of
the end product during manufacturing of bulk
drugs. Such types of impurities are common in the
medicines as they result from improper storage of
formulation. The degradation of penicillins and
cephalosporins is a well-known example of
degradation products
4
. The presence of a ß-lactam
ring as well as that of an α-amino group in the
C6/C7 side chain plays a critical role in their
degradation.
5
In general, an individual API may contain all of
the above mentioned types of organic impurities
at various levels ranging from negligible to
significant amount. As the organic impurities are
the most common product related impurity as well
as the process related impurity, it is the
responsibility of both the manufacturers of APIs
and formulators to take care of these impurities
according to ICH guidelines or compendia.
Inorganic Impurities
Inorganic impurities are also obtained from the
manufacturing processes which are used in bulk
drugs formulation. They are normally known and
identified. It includes impurities like heavy metal
impurities, other material impurities (filter aids,
charcoal) and residual solvent impurities.
Heavy Metals Impurities
The main source of heavy metals is water which
is generally used in different manufacturing
processes, where acidification or acid hydrolysis
takes place. These impurities of heavy metals can
easily be avoided by using demineralized water
and glass-lined reactors.
Other Materials (Filter Aids, Charcoal)
Impurities
The filters or filtering aids such as centrifuge bags
are routinely used in the bulk drugs
manufacturing plants and in many cases, activated
carbon is also used which also act as a source of
impurity. Therefore regular monitoring of fibers
and black particles in the bulk drugs is essential
so as to avoid their contaminations
6
.
Residual Solvent Impurities
It is very difficult to remove these solvents
completely by the work-up process.
7,8
However,
efforts should be taken to the extent possible so as
to meet the safety data. Some solvents that are
known to cause toxicity should be avoided in the
production of bulk drugs. Depending on the
possible risk to human health, residual solvents
are divided into 3 classes.
Renu Solanki et al. / International Journal of Drug Research and Technology 2012, Vol. 2 (3), 231-238
http://www.ijdrt.com 233
Solvents of class I included benzene (Class I, 2
ppm limit) and carbon tetrachloride (Class I, 4
ppm limit). These are to be avoiding because of
their carcinogenic, toxicity effects.
On the other hand, solvents of class II includes
methylene chloride (600 ppm), methanol
(3000 ppm), pyridine (200 ppm), toluene (890
ppm), N, N-dimethylformamide (880 ppm) and
acetonitrile (410 ppm).These are most commonly
used solvents.
Solvents of class III includes acetic acid, acetone,
isopropyl alcohol, butanol, ethanol and ethyl
acetate have permitted daily exposures of 50 mg
or less per day. In this regard, ICH guidelines for
limits should be strictly followed.
Process Based Impurities
Apart from bulk drug-related impurities, the
formulated form of API may contain impurities
that are formed in various ways during the
processing of the drug like impurity obtained due
to method defect, impurity obtained due to
environmental defect, impurity obtained due to
factor defect, impurities formed due to mutual
interaction among ingredients and impurities
formed due to functional group reaction
degradation.
Impurity Obtained Due To Method Defect
Impurity related to method may be caused by
improper manufacturing processes which don’t
follow the optimized conditions like pressure,
temperature during processing.
9
Eg. 1-(2, 6-
diclorophenyl) indolin-2-one is formed as
impurity in the production of a parenteral dosage
form of diclofenac sodium
10
, if it is terminally
sterilized by autoclave. It was the condition of the
autoclave method (i.e., 123 + 2°C) that enforced
the intramolecular cyclic reaction of diclofenac
sodium forming the indolinone derivative and
sodium hydroxide. Formation of such impurity
also depends on the initial pH of the
formulation.
11
Impurity Obtained Due To Environmental
Defect
The primary environmental factors that can
reduce stability include the following: Exposures
to adverse temperatures, there are many APIs that
are labile to heat or tropical temperatures. Eg.
vitamins as drug substances are very heat-
sensitive and get degradated frequently leading to
loss of potency in vitamin products, especially in
liquid formulations. Light-especially UV light
causes initiating a large number of systems that
are photolyzed; and causes formation of free
radicals as end products.
12
Several studies have
reported that ergometrine as well as methyl
ergometrine injections are unstable under tropical
conditions such as light and heat.
Impurity Obtained Due To Factor Defect
Although the pharmaceutical companies perform
pre-formulation studies, including stability studies
before marketing the products, sometimes the
dosage form factors influence the drug stability
and forces the company to recall the product.
Fluocinonide Topical Solution USP, 0.05%,
(Teva Pharmaceuticals USA, Inc., Sellersville,
Pennsylvania) in 60-ml bottles was recalled in the
United States because of degradation/impurities
leading to sub-potency. In general, liquid dosage
forms are very much susceptible to both
degradation and microbiological contaminations.
In this regard, water content, pH of the
solution/suspension, compatibility of anions and
cations, mutual interactions of ingredients and the
primary container are also some critical factors.
Microbiological growth resulting from the growth
of bacteria, fungi and yeast in a humid and warm
environment may result in oral liquid products
that are unusable and unsafe for human
consumption.
Impurities Formed Due To Mutual Interaction
Among Ingredients
Most vitamins are very labile and on ageing they
pose a problem of instability in different dosage
forms, especially in liquid dosage forms.
Degradation of vitamins such as folic acid,
pantothenic acid, cyanocobalamin and thiamine
do not give toxic impurities. However, potency of
active ingredients drops below pharmacopoeial
specifications. Because of mutual interaction the
Renu Solanki et al. / International Journal of Drug Research and Technology 2012, Vol. 2 (3), 231-238
http://www.ijdrt.com 234
presence of nicotinamide in a formulation
containing 4 vitamins (nicotinamide, pyridoxine,
riboflavin, and thiamine) causes the degradation
of thiamine to a sub-standard level within a 1-year
shelf-life of vitamin B-complex injections. The
marketed samples of vitamin B-complex
injections were found to have a pH in the range of
2.8-4.0. The custom made formulation in a simple
distilled-water vehicle and in a typical formulated
vehicle that included disodium editate and benzyl
alcohol was also investigated and similar mutual
interaction causing degradation were also
observed.
Impurities Formed Due To Functional Group
Reaction Degradation
Degradation products of drugs are considered to
be transformation products of the drug substance
formed due to the effect of heat, solvents
(including high and low pH), oxidising agents,
other chemical reagents, humidity and light.
12,13
Hydrolysis
Hydrolysis is a common phenomenon for ester
and amide type of drugs, especially in liquid
dosage forms. Certain drugs which undergo
hydrolysis are benzylpenicillin, barbitol,
chloramphenicol, chlordiazepoxide, lincomycin
and oxazepam.
13
Oxidation
The oxidative decomposition of pharmaceutical
compounds is responsible for the instability of a
considerable number of pharmaceutical
preparations. These reactions are mediated either
by free radicals or by molecular oxygen. Drugs
which undergo oxidative degradation are
hydrocortisone, methotrexate, adinazolam,
hydroxyl group directly bonded to an aromatic
ring (eg, phenol derivatives such as
catecholamines and morphine), conjugated dienes
(eg, vitamin A and unsaturated free fatty acids),
heterocyclic aromatic rings, nitroso and nitrite
derivatives and aldehydes (eg, flavorings).
Decarboxylation
Some dissolved carboxylic acids such as p-amino
salicylic acid, lose carbon dioxide from the
carboxyl group when heated. Decarboxylation
also occurred in the case of photoreaction of
rufloxacin.
Photolysis
Pharmaceutical products are bared to light while
being held improperly in pharmacy shops or
hospitals, or when held by the consumer for
imminent use. Drugs which undergo photolytic
cleavage are ergometrine, nifedipine,
nitroprusside, riboflavin and phenothiazines are
very labile to photo-oxidation. In vulnerable
compounds, photochemical energy creates free
radical intermediates, which can accomplish by
chain reactions. Most compounds degrade as
solutions when bared to high energy UV
exposure. Fluoroquinolones antibiotics are found
to be susceptible to photolytic cleavage. In
ciprofloxacin eye drops preparation (0.3%),
sunlight induces photo cleavage reaction
producing ethylenediamine analog of
ciprofloxacin.
GUIDELINES FOR IMPURITY PROFILE
It is now getting important critical attention from
regulatory authorities. The different
pharmacopoeias, such as the British
Pharmacopoeia (BP), the United States
Pharmacopoeia (USP) and the Indian
Pharmacopoeia (IP) are slowly incorporating
limits to allowable levels of impurities present in
the APIs or formulations. Also, the International
Conference on Harmonization (ICH) has
published certain guidelines on impurities in drug
substances, products and residual solvents. There
is a significant demand for the impurity reference
standards and the API reference standards for
both regulatory authorities and pharmaceutical
companies. According to ICH guidelines on
impurities in new drug products, identification of
impurities below 0.1% level is not considered to
be necessary, unless potential impurities are
expected to be unusually potent or toxic. Limits
for impurities in drug substances are shown in
table1 while limits for impurities in degraded
products of drugs are shown in table 2.
Renu Solanki et al. / International Journal of Drug Research and Technology 2012, Vol. 2 (3), 231-238
http://www.ijdrt.com 235
Specifications should be set for identified and
unidentified impurities expected to be present in
the drug substances and drug products over the
period of intended use and under recommended
storage conditions. These impurities are known as
specified impurities and they should be
individually listed in the specifications. Stability
studies, chemical development studies and routine
batch analyses can be used to establish impurities
likely to occur in the commercial new drug
substances and new drug products. A general
specification limit of not more than 0.1% for any
unspecified impurity should also be included. A
rationale for why impurities were included or
excluded from the specifications for the drug
substance and drug products should be provided.
Limits for impurities should be set no higher than
the level which can be justified by safety data and
unless safety data indicate otherwise, no lower
than the level achievable by the manufacturing
process and the analytical capability.
ANALYTICAL METHOD DEVELOPMENT
AND VALIDATION FOR IMPURITY
PROFILE14-22
The impurities can be identified predominately by
methods like reference standard method,
spectroscopic method, separation method,
isolation method and characterization method.
Reference Standard Method
The key objective of this is to provide clarity to
the overall life cycle, qualification and
governance of reference standards are used in the
development and control of new drugs. Reference
standards serve as the basis of evaluation of both
process and product performance and are the
benchmarks for assessment of drug safety for
patient consumption. These standards are needed
not only for the active ingredients in dosage forms
but also for impurities, degradation products,
starting materials, process intermediates and
excipients.
Spectroscopic Method
The UV, IR, MS, NMR and Raman spectroscopic
methods are routinely being used for
characterizing impurities.
Separation Method
Capillary Electrophoresis (CE), Gas
Chromatography (GC), Supercritical Fluid
Chromatography (SFC), Thin Layer
Chromatography (TLC), High Performance Thin
Layer Chromatography (HPTLC), High
Performance Liquid Chromatography (HPLC) are
regularly being used for separation of impurities
and degradation products.
Isolation Method
It is often necessary to isolate impurities. But if
the instrumental methods are used, isolation of
impurities is avoided as it directly characterizes
the impurities. Generally, chromatographic and
non chromatographic techniques are used for
isolation of impurities prior to its characterization.
The term ‘chromatographic reactor’ refers to the
use of an analytical-scale column as both flow-
through reactor and simultaneously, as separation
medium for the reactant(s) and product(s). By
using an HPLC, chromatographic reactor
approach, the solution-phase hydrolysis kinetics
of the Aprepitant (EmendTM) prodrug, for
aprepitant dimeglumine, were investigated. In
loratidine, impurity found was ofloratidine.
Other
examples include celecoxib and amikacin. A list
of methods that can be used for isolation of
impurities are solid-phase extraction methods,
liquid-liquid extraction methods, accelerated
solvent extraction methods, supercritical fluid
extraction, column chromatography, flash
chromatography, capillary electrophoresis (CE),
gas chromatography (GC), thin layer
chromatography (TLC), high performance thin
layer chromatography (HPTLC), high
performance liquid chromatography (HPLC),
supercritical
本文档为【IMPURITY PROFILING OF ACTIVE PHARMACEUTICAL INGREDIENTS】,请使用软件OFFICE或WPS软件打开。作品中的文字与图均可以修改和编辑,
图片更改请在作品中右键图片并更换,文字修改请直接点击文字进行修改,也可以新增和删除文档中的内容。
该文档来自用户分享,如有侵权行为请发邮件ishare@vip.sina.com联系网站客服,我们会及时删除。
[版权声明] 本站所有资料为用户分享产生,若发现您的权利被侵害,请联系客服邮件isharekefu@iask.cn,我们尽快处理。
本作品所展示的图片、画像、字体、音乐的版权可能需版权方额外授权,请谨慎使用。
网站提供的党政主题相关内容(国旗、国徽、党徽..)目的在于配合国家政策宣传,仅限个人学习分享使用,禁止用于任何广告和商用目的。